Podcasts about 3C

GGG released patch 0.3.0c this week! So, in episode 310, we discuss our gameplay before and after the patch, and the build ideas and progress we've made so far. New content, especially in a beta, comes with it's list of good and bad additions, and the glorious thing about sharing that with people is that sometimes they agree with you, and sometimes they don't! The person writing this, is of course, always right...but don't tell my co-host that.Thanks for all of your support as we reach episode 310! You're amazing! Thank you! (00:00:00) Welcome to Forever Exiled(00:04:50) Streaming services and subscriptions(00:11:42) Moving off Google Photos project(00:18:20) Back pain struggles and cutting things out(00:25:30) School updates and teacher frustrations(00:33:40) Gardening debates and family interactions(00:43:55) Difficult decision about Riley the dog(00:47:10) Path of Exile date night gaming(00:55:40) Leveling up frustrations and co-op dynamics(01:03:05) Patch 3.0.3C highlights and fixes(01:12:12) Performance issues and framerate drops(01:20:15) Blood Mage build discussion and leveling challenges(01:27:20) Campaign feedback and final thoughtsForever Exiled Info:www.foreverexiled.comPatreonTwitter @ForeverExiled82Path of Exile WebsiteWrecker of Days Builds ListDiscord...FE Merch StoreFE Nexus Store

In this episode of The Brand Called You, Steve Walsh — FinTech entrepreneur, investor, and author of Make the 10X Leap shares his journey, the 3C framework (Clarity, Confidence, Clairvoyance), and how entrepreneurs can break through stalls, raise the right capital, and scale fearlessly.00:54- About Steve WalshSteve is the founder of Bison Equity Group, which is dedicated to supporting entrepreneurs and investors in achieving success with high potential companies.He's an author of a book titled Make the 10X Leap.

一、【20250827人間菩提】因核果海甚微妙 「因核果海」，一粒微小的因子，若有因緣滋養，能繁衍無量善果。慈濟的歷程正是如此：從「五毛錢」起步，一路延展，如今慈濟的慈善援助已遍及全球五大洲，海外志工遍布56個國家地區，印證了「極微小不可輕視」，點滴愛心能匯聚成無量功德。宗教的核心不在名相，而是善與愛，讓慈悲持續在人間流轉。 二、大愛中醫館~白露養生：保暖、防燥與心情調適 白露是秋季的第三個節氣，天氣轉涼，早晚溫差大，空氣逐漸乾燥，正是養生的重要時機。俗語「白露生，身不露」，提醒我們此時要注意保暖，避免受涼導致筋骨痠痛或感冒。另一方面，「不露」也意指情緒容易低落，秋冬交替常見心情鬱悶、無精打采，甚至影響心理健康，因此除了身體保養，也要照顧心靈。 慈濟大學後中醫學系助理教授柯建新醫師分享，在中醫觀點，秋屬金，對應肺與大腸。此時最需防燥，因乾燥不僅會導致喉嚨不適、皮膚乾裂，也可能引發便秘、氣喘、乾眼症等症狀。建議多補充水分，避免過度食用辛辣或堅果，以免加重乾燥感。現代人長時間使用3C產品，眼睛乾澀更加明顯，更需注意飲食與水分調節。 飲食方面，可適量攝取白色食材如白木耳、百合、山藥、蓮子、水梨等，有助於潤肺養陰。四神湯也是適合秋季的滋養料理，能兼顧健脾與護肺。柚子則是白露後的時令水果，雖然能通便，但因屬涼性，體質虛寒或腸胃較弱者應謹慎食用，且柚子與部分藥物可能產生交互作用，高血壓、糖尿病等慢性病患者需特別留意，最好諮詢藥師。 另外，中秋節常見的月餅、甜飲，糖分與熱量高，不宜過量，尤其對於慢性病患者，應該「淺嚐即止」，避免因貪嘴而造成血糖、血脂失控。若想潤喉，可選擇處理過的陳皮入茶，避免未經處理的柑橘皮帶來刺激。 總而言之，白露養生重點在三：第一，注意保暖，避免「秋老虎」與早晚溫差造成的受寒；第二，防燥潤肺，多攝取水分與滋潤食材；第三，調整心情，避免秋季憂鬱。把握飲食、起居與情緒的調養，才能平穩過渡季節變化，迎向健康的秋冬。

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

本集我邀請到朱楚文老師，帶大家深入探討如何運用高情商溝通技巧，透過如「鸚鵡回應法」和「3C應對策略」等獨門心法，不僅能化解家庭與職場中的溝通困境，更能快速建立信任、掌握對話主導權，讓每一段對話都充滿深度與連結！ 【職場提問回應力】

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

1. GOD HAS A PLAN FOR YOUR CHILD Jeremiah 29:11 For I know the plans I have for you,” declares the Lord, “plans to prosper you and not to harm you, plans to give you hope and a future. (NIV) 1A. VANITY PARENTING 1B. PERFECTION PARENTING 1C. RESCUE PARENTING 1D. COMPETITIVE PARENTING 2. GOD’S PLAN AND THE WORD OF GOD 2A. LOVE THE WORD OF GOD Joshua 1:8 Keep this Book of the Law always on your lips; meditate on it day and night, so that you may be careful to do everything written in it. Then you will be prosperous and successful. (NIV) 1. EMOTIONS 2. EXPERIENCES 3. FAMILY 4. FRIENDS 5. TRADITION 6. CULTURE 3. GOD’S PLAN AND THE HOUSE OF GOD Psalm 84:10 Better is one day in your courts than a thousand elsewhere; I would rather be a doorkeeper in the house of my God than dwell in the tents of the wicked. (NIV) Psalm 92:13 planted in the house of the Lord, they will flourish in the courts of our God. (NIV) A. GODLY FRIENDS B. GODLY MENTORS 3A. YOU NEED TO LOVE AND BE PASSIONATE ABOUT GOD’S HOUSE 3B. DON’T TALK BAD ABOUT CHURCH 3C. SERVE AT CHURCH 3D. EARLY ON HELP YOUR KIDS SERVE OTHERS 3E. GET YOUR KIDS ON THE DREAM TEAM AS SOON AS POSSIBLE 4. GOD’S PLAN AND THE VOICE OF GOD John 10:27 My sheep listen to my voice; I know them, and they follow me. (NIV) TIPS ON TEACHING YOUR CHILDREN TO HEAR THE VOICE OF GOD 4A. PRAY TOGETHER AS A FAMILY 4B. ASK YOUR KIDS WHAT GOD IS SPEAKING TO THEIR HEART 4C. ASK YOUR KIDS WHAT GOD IS SPEAKING TO THEM FROM THE WORD OF GOD 4D. ASK YOUR KIDS TO PRAY AND PROCESS THEIR YEARLY GOALS 4E. TEACH YOUR KIDS TO PRAY AND TO MAKE DECISIONS

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

中國信託聯手統一集團推出uniopen聯名信用卡 2025年12月31日前消費享最高11%回饋 完成指定任務加碼每月免費跨行轉帳10次，ATM存領外幣各1次免手續費 申辦中國信託uniopen信用卡> 了解詳情> https://sofm.pse.is/837spk 謹慎理財 信用至上 －－－－以上為 SoundOn 動態廣告－－－－ DJ：陶晶瑩（飛碟電台） 週一至五 首播 17:00​​​​​​​​​​​​​​-18:00​​​​​​​​​​​​​​ 週六 精華重播 19:00​​​​​​​​​​​​​​-21:00 ※網站真假難辨？提醒注意網路詐騙新手法！ ※別耍太多廢在滑手機上！對日常生活作息的負面影響。 ※現代人想戒斷3C成癮真的不容易嗎？ ※日本京都觀光景點貴船川沿岸一家餐廳的川床設施發生坍塌意外。 飛碟聯播網 提醒關心您： ※酒後不開車，飲酒過量有礙健康，未成年請勿飲酒。 ※自我傷害不能解決問題，勇敢求救並非弱者，請珍惜生命。衛福部24小時安心專線：1925，張老師：1980，生命線：1995。 ※尊重身體自主權，遇到性騷擾勇於制止，勇敢說不！報案：110，保護專線：113，婦女救援基金會：02-2555-8595，勵馨基金會：02-8911-8595。 ※拒絕暴力，如遇霸凌請勇於求助，反霸凌專線：1953，教育部投訴專線：0800-200-885，iWIN網路防護機構諮詢專線：02-2577-5118。 ※任何人在依法被判決有罪確定前，均應推定為無罪。 陶晶瑩 ●Instagram：https://www.instagram.com/momoleelee/ ●facebook：https://www.facebook.com/people/%E9%99%B6%E6%99%B6%E7%91%A9/100044575080077/ 按讚 訂閱 分享 開啟小鈴鐺 -- Hosting provided by SoundOn

親愛的朋友，要解決孩子對3C的癮頭，或許用天父的愛，來滿足內在真實的需求，會更有效果；讓我們一起用禱告，求神在兒女的心中，動奇妙的善工，幫助家裡的年輕人建立蒙福的生活。 【聖經中的祝福】 因為我要將水澆灌口渴的人，將河澆灌乾旱之地，我要將我的靈澆灌你的後裔，將我的福澆灌你的子孫。（以賽亞書 44:3） 【為兒女禱告】 天父，祢知道我身為父母的疲倦，對於教養有太多無奈跟無力感；求我在天上的父，再多賜下愛人的力量，使我有耐心繼續跟兒女的手機對抗。 同時求祢在我管不動、說不聽的地方動工；教我學會將對兒女的擔憂，先交託在祢能挽回人心的手中。 讓我的孩子不單已我為榜樣，更已基督為榜樣；在恩典的真理中，建立自尊、自愛的品格，知道自己的身體是聖靈的殿，就懂得享受自律又健康的生活作息。 並且，積極的探索、規劃在祢美意裡的將來；讓我的兒女有智慧拒絕3C的綑綁，趁著年輕把根基建立在祢的豐盛之上。 感謝天父垂聽我的禱告，奉主耶穌的聖名祈求，阿們。 -- Hosting provided by SoundOn

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

《360°生活家》－全面升級你的日常！ 想一次掌握生活資訊、科技新知、3C智慧、歷史故事與健康趨勢嗎？ 《360°生活家》每集帶你從不同角度探索生活的無限可能 無論是科技新品開箱、健康生活技巧，還是日常小撇步 都能讓你輕鬆成為生活達人，開啟更有品質的精彩人生！ 現在就跟著我們，360度全面升級你的生活吧！ 歡迎訂閱、收聽，每日更新精彩內容 陪你一起輕鬆享受智慧、健康、便利的美好生活！

Dating And Sex As A Disciple Matthew 16:24 Then Jesus said to His disciples, “If anyone DESIRES to come after Me, let him deny himself, and take up his cross, and follow Me. (NKJV) Matthew 22:36-40 “Teacher, which is the greatest commandment in the Law?” 37 Jesus replied: “‘Love the Lord your God with all your heart and with all your soul and with all your mind.’  38 This is the first and greatest commandment. 39 And the second is like it: ‘Love your neighbor as yourself.’  40 All the Law and the Prophets hang on these two commandments.” (NIV) 1. LOVE GOD FIRST   2. LOVE YOURSELF SECOND Matthew 22:39 And the second is like it: ‘Love your neighbor as yourself.’ (NIV) 2A. GET YOUR IDENTITY RIGHT Genesis 1:27 So God created mankind in his own image, in the image of God he created them; male and female he created them. (NIV) Mark 10:6–7 “ But at the beginning of creation God ‘made them male and female.’ 7 ‘For this reason a man will leave his father and mother and be united to his wife, (NIV) 2B. GET YOUR MIND AND EMOTIONS RIGHT Philippians 4:6–7   Do not be anxious about anything, but in every situation, by prayer and petition, with thanksgiving, present your requests to God. 7 And the peace of God, which transcends all understanding, will guard your hearts and your minds in Christ Jesus. (NIV) Matthew 6:34 Therefore do not worry about tomorrow, for tomorrow will worry about itself. Each day has enough trouble of its own. (NIV) Psalm 147:3 He heals the brokenhearted and binds up their wounds. (NIV) Romans 12:2 Do not conform to the pattern of this world, but be transformed by the renewing of your MIND. Then you will be able to test and approve what God’s will is—his good, pleasing and perfect will. (NIV) 2 Timothy 1:7 For God has not given us a spirit of fear, but of power and of love and of a sound MIND. (NKJV) 2C. GET YOUR CAREER RIGHT 2D. GET YOUR CREDIT SCORE AND MONEY RIGHT 3. LOVE YOUR NEIGHBOR THIRD 3A. GO SLOW AND GET TO KNOW Proverbs 19:2–3 Enthusiasm without knowledge is no good; haste makes mistakes. 3 People ruin their lives by their own foolishness and then are angry at the LORD. (NLT) 3B. DATE FOR PROOF NOT POTENTIAL Matthew 12:33   “Make a tree good and its fruit will be good, or make a tree bad and its fruit will be bad, for a tree is recognized by its fruit. (NIV) 3C. KEEP YOUR SEXUAL DESIRES IN CHECK 1 Corinthians 6:18 Flee from sexual immorality. All other sins a person commits are outside the body, but whoever sins sexually, sins against their own body. (NIV) 1 Thessalonians 4:3 It is God’s will that you should be sanctified: that you should avoid sexual immorality; (NIV)

本期主播：马客、小梁、猛哥、天一、大雄、史炎马客（唱片收藏爱好者）小梁（@梁彦增）猛哥（@猛哥天才捕手）（「天才捕手FM」主播）天一（小红书：天一 stand-up comedian）大雄（@大雄稳不稳）史炎（@史炎nacl）本期节目几位主播聊聊「收集和收藏」，战损收藏、赛博收藏、3C收藏…收藏的类目真不少，竟然还有人收藏破鞋？！收藏其实是一种占有欲？什么！史炎老师在录制时当场换裤子？…收藏很多时候不仅是收藏一个物件，还有它背后的故事、情感和时光…希望大家都能拥有自己珍爱的收藏~时间轴：00:06:54 音乐收藏家的黑胶唱片之旅00:10:23 奇趣收藏与文创周边00:17:15 那些战损收藏00:22:14 黑胶唱片的复兴之路00:45:02 球星卡与球衣收藏00:50:01 发烧友之间的交流探讨01:06:30 签名版是贬值还是升值01:19:07 被收藏的青春与童年回忆01:39:31 那些因为收藏而收获的友情01:51:08 那些为爱发电的收藏行为02:01:43 每一个“当下”都值得收藏不开玩笑热卖周边：除了收听播客，也欢迎支持我们的热卖周边哦！微信搜索猫头鹰喜剧小程序→商城→好物，购买即刻拥有主播同款周边哦！线下演出：冰冰的脱口秀专场《不懂事儿》正在全国巡演！将会去到多个城市，希望能和大家见面！具体开票及购票信息请到公众号：万冰冰脱口秀每周在北京和上海还有我们的脱口秀演出，微信搜索小程序「猫头鹰喜剧」，线下脱口秀演出等你来～来相爱：【听友群】公众号“猫头鹰喜剧”回复“听友群”，小助手会把你拉进群聊哦～【微博】@不开玩笑JokesAside【小红书】@不开玩笑【抖音】@不开玩笑商务合作：欢迎发送邮件至 lvtianxiong@yeah.net音乐采样：Al Bowlly - The Very Thought of YouTortoise - Cliff Dweller Society策划：史炎、大雄、马军剪辑：「内容中苔创作中心」孔老师发布：冰块

父親節 fù qīn jié - Father's Day華盛頓州 Huá shèng dùn zhōu - Washington State (in the USA)辛苦 xīn kǔ - hard; toilsome; full of hardship玫瑰 méi guī - rose (flower)紀念 jì niàn - to commemorate; in memory of由來 yóu lái - origin; source溫馨 wēn xīn - warm and sweet; heartwarming豪華 háo huá - luxurious; fancy皮夾 pí jiá - wallet皮帶 pí dài - belt實用 shí yòng - practical; useful三c產品 sān C chǎn pǐn - 3C products (computer, communication, and consumer electronics)平板 píng bǎn - tablet金門高粱酒 Jīn mén gāo liáng jiǔ - Kinmen Kaoliang liquor 按摩椅 àn mó yǐ - massage chair筋骨鬆一下 jīn gǔ sōng yí xià - relax the muscles and bones; to loosen up and relieve physical tensionFeeling stuck or frustrated with your Chinese progress? Book a one-on-one trial lesson with me

蕭彤雯 主持 生活同樂會

Single And Satisfied Matthew 16:24 - Then Jesus said to His disciples, “If anyone desires to come after Me let him deny himself, and take up his cross, and follow Me. (NKJV) Genesis 2:18 The Lord God said, “It is not good for the man to be alone. I will make a helper suitable for him.” (NIV) Proverbs 18:22 He who finds a wife finds what is good and receives favor from the Lord. (NIV) 1 Corinthians 7:8 So I say to those who aren’t married and to widows—it’s better to stay unmarried, just as I am. (NLT) 1. DISCOVER THE GIFT OF SINGLENESS 1 Corinthians 7:7–8 I wish that all of you were as I am. But each of you has your own GIFT from God; one has this gift, another has that. 8 Now to the unmarried and the widows I say: It is good for them to stay unmarried, as I do. (NIV) 2. DESIRE FOR MARRIAGE DOES NOT HAVE TO EQUAL DISCONTENTMENT IN LIFE 1 Corinthians 7:28 But if you do marry, you have not sinned; and if a virgin marries, she has not sinned. But those who marry will face many troubles in this life, and I want to spare you this. (NIV) 2A. RECOGNIZE THAT DESIRE AND CONTENTMENT ARE TWO DIFFERENT THINGS Philippians 4:11-13 I am not saying this because I am in need, for I have learned to be content WHATEVER the circumstances. 12 I know what it is to be in need, and I know what it is to have plenty. I have learned the secret of being content in any and every situation, whether well fed or hungry, whether living in plenty or in want. 13 I can do all this through him who gives me strength. (NIV) 2B. SEE GOD’S GOODNESS IN YOUR SINGLENESS, NOT APART FROM IT 3. DISCERN THE ADVANTAGES OF SINGLENESS 3A. FREEDOM 1 Corinthians 7:32-33 I would like you to be free from concern. An unmarried man is concerned about the Lord’s affairs—how he can please the Lord. 33 But a married man is concerned about the affairs of this world—how he can please his wife— (NIV) 3B. FLEXIBILITY 3C. FOCUS 1 Corinthians 7:34–35 and his interests are divided. An unmarried woman or virgin is concerned about the Lord’s affairs: Her aim is to be devoted to the Lord in both body and spirit. But a married woman is concerned about the affairs of this world—how she can please her husband. 35 I am saying this for your own good, not to restrict you, but that you may live in a right way in UNDIVIDED DEVOTION to the Lord. (NIV)

Send us a textWe're more connected than ever and yet so many of us feel more alone, more depleted, more fractured. From the rise of remote work to the silent pull of AI companions and parasocial relationships, something fundamental has shifted in how we show up for each other.Join Anna and Tim as they unpack the structural, cultural, and emotional forces reshaping our relationships. This episode is a call to awareness, not despair, and it offers real questions and micro-practices for rebuilding meaningful connection. Whether you're grieving lost intimacy, navigating political estrangement, or feeling hollow in a world of endless scrolling, you're not alone.This Episode Covers:How AI is changing intimacy, coaching, and even friendshipThe mental health fallout from social isolation post-COVIDWhy political division is estranging families more than geographyParasocial relationships and the illusion of belongingWhy “mosting” is the new ghosting and how it hijacks your brainThe loneliness epidemic and its physical health consequencesWhy Gen Z is stuck in situationships and emotional ambiguityA powerful 3C audit to help you reconnect todayUntil next time, here's to deeper connections and personal growth.Mad love!The podcast is now on YouTube! If you prefer to watch, head over to https://www.youtube.com/playlist?list=PLw3CabcJueib20U_L3WeaR-lNG_B3zYqu__________________________________________Don't forget to subscribe to the Badass Confidence Coach podcast on your favorite podcast platform!CONNECT WITH ANNA:Instagram https://www.instagram.com/askannamarcolin/TikTok https://www.tiktok.com/tag/askannamarcolinEmail hello@annamarcolin.comWebsite https://www.annamarcolin.com

欢迎收听雪球出品的财经有深度，雪球，国内领先的集投资交流交易一体的综合财富管理平台，聪明的投资者都在这里。今天分享的内容叫美团阿里开始豪赌未来，来自王智远同学。7月5号，阿里淘宝闪购突然发起一场名为“淮海战役”的补贴大战，目标很明确：每周六集中火力冲单量。阿里为什么要主动发起这样一场战役？战略意图是什么？01我觉得，阿里真正想赢的，是淘宝未来。为什么这么说？因为淘宝这套传统货架模式的增长已经接近天花板，年增长率不到10%，明显放缓；而另一边，即时零售——也就是外卖+快消品——仍在以超过20%的速度增长。这说明，人们越来越习惯“马上要、立刻有”的消费方式。阿里在思考：如果我能把用户从“一个月逛几次淘宝”，变成“一周点好几单外卖”，那不就等于给淘宝装上了一个新的发动机？而且，这个发动机很猛。外卖是高频行为，每天都要吃饭、喝咖啡、买零食。一旦用户习惯了通过淘宝闪购点外卖，就会开始顺手买点别的东西。比如：7月5日当天，淘宝闪购的粮油、母婴、家电等品类订单同比增长超100%。用户开始像“双11囤货”一样，囤起了即时消费品。再来看一组数据：截至7月5日22时54分，淘宝闪购非餐饮类订单已达1300万单，相比一年前翻了6倍；美团同期也有约2000万单是非餐饮交易。这说明，两个平台都在试图用外卖带动零售，谁先养成就用户习惯，谁就能赢得主动权。阿里还有一个别人难以复制的优势：流量太大。QuestMobile数据显示，2025年1至5月，淘宝App日活用户增长至4.1亿，美团外卖日均支付订单维持在9000万以上。7月5日那天阿里直接将所有App开屏广告全换成橙色促销，一下触达了几亿人；这种打法，美团根本接不住。更狠的是，阿里还把饿了么和支付宝深度绑定。你点个外卖，顺便就把支付宝用了；如果你是88VIP会员，还能直接送你一个饿了么会员。这种生态联动，让整个消费路径变得更顺畅，也更容易留住用户。当然，美团也不是没有反击能力。它同样能靠补贴冲单量，1亿单的规模随时可以做到；但问题在于，美团不像阿里那样拥有庞大的流量池，也没有那么多可补的零售品类支撑这场战争。还有一个关键时间窗口，阿里必须抢在前面出手。因为美团也在悄悄打造自己的“零售版淘宝”，它的闪购业务已占GMV的15%，涵盖超市、便利、数码家电等多个品类。换句话说，它不只是要做外卖，还想做更多。但目前，它的商品丰富度尚未完全上来，尤其在生鲜、母婴等高毛利品类上。这时，阿里突然出手，就像在美团盖楼之前，先把脚下的地基给挖松了。如果你仔细看淘宝闪购公布的数据，会发现一个有意思的细节：粮油米面、冷冻食品、家清、母婴、个护等品类的订单增速最快。这说明，阿里正在借助外卖打开用户的生活圈，所以回过头看这场战役，智远主观分析认为，阿里的战略目的有三：一，改造淘宝，用外卖的高频需求激活用户活跃度；二，拖住美团，逼它在补贴战中持续消耗现金流；三，抢占心智，让“30分钟送达”成为淘宝的新标签。换句话说，阿里想借外卖的风，把淘宝吹向一个新阶段。02不过，美团也不是没有反击能力。它只用12个小时，就把订单量从日常的9000万单提升到1.2亿单，直接冲上历史峰值。这波操作可以说是“闪电反击”，也再次展示了美团在外卖战场上的硬实力，它靠一套真刀真枪打磨出来的配送系统。它手里握着全国最大的即时配送网络，700万骑手中，日均活跃的有336万，占整个中国即时配送市场的60%以上。换句话说，全国每10个送外卖的人里，就有6个是美团的。除了自有运力，它还有麦芽田和青云两大聚合平台，这两个系统可以整合大量第三方配送公司，单日最高调度能力超过1000万单。更关键的是，它的动态定价机制。高峰期时，骑手每单奖励能飙到10元，但美团仍基本保证了餐品按时送达。听起来是不是很稳？但这场比赛也暴露了一个问题：系统虽然强大，也有自己的天花板。比如，7月5日晚高峰时，订单突然暴涨，导致美团旗下麦芽田服务器一度崩溃，部分订单延迟了1到2小时；这种事在日常可能还能扛得住，但在极限对战中，就容易出问题。而且别忘了，光为了维持这个系统的运转，美团每天就要烧掉两亿多的补贴成本。你说这能撑多久？再来看另一个角度：美团在非餐饮品类布局远超竞对。它有自己的前置仓体系，加上3万多加盟闪电仓，在北京望京区域，三公里范围内就能覆盖20万个SKU，而传统超市如沃尔玛，通常只有3万个左右。什么概念？它真的能做到“你要什么我都能送”，但背后的问题也很明显：模式太重，利润太薄。美团2024年全年经营利润为368亿元，其中外卖贡献约325亿元；但今年的补贴支出将在去年基础上新增至少100亿元，如果下半年竞争加剧，还可能增加150亿到200亿元。同时，美团闪购是重资产路线，毛利率仅为20%-25%，客单价65元，履约成本却高达8元，虽然这一差距相比外卖业务正在缩小，但整体压力依然不小。再加上3万多家加盟闪电仓和自营前置仓，每天的维护成本都超过千万。相比之下，阿里那500亿补贴分摊到12个月，平均每天不到1.4亿，和美团日常营销支出已相当接近。这就像一场耐力赛，看谁更能耗。最危险的信号出现在哪里？是美团开始发放“用户自提免单券”，这是它在用一种损害用户体验的方式去止损。已有用户反馈说“缺货”或“覆盖范围有限”，说明这套模式仍在探索阶段。你看，运力已经快到极限了，但它还不能停。所以回过头看这场“1.2亿单反击战”，你会发现：美团的护城河确实很深，短期内没人能轻易撼动；但它维护这座护城河的成本太高，就像一边建城墙，一边还要不停往里面灌水泥；它现在面对一个带着生态打法来的超级平台。03这场仗打得越狠，就越有人在替平台“买单”，真正承受代价的，还有商家、骑手，甚至整个行业的生态平衡。智远了解到，不少连锁品牌接到通知时已经是下午：“今天要冲单量，你们得配合。”听起来像是临时加戏，但对商家来说，这是一场突如其来的“硬仗”。人力成本飙升，他们不得不临时高薪请人打包，甚至找兼职帮忙。如果真爆单了还好，一旦没爆单，牛奶、水果等原料只能白白浪费。再来看平台这边。以美团1.2亿单为例：每天光是直接补贴就得花掉12亿元，还有大量隐性支出——服务器扩容、投诉赔偿、骑手保险……这些账单藏在后台，没人看见，却一样都不能少。换句话说，这是一次对整个运营系统的极限测试。再看一个容易被忽略的群体：小商户和区域品牌。在这场战斗中，受益最多的还是头部连锁品牌。像一些大型连锁奶茶店，接到通知后能立刻调动IT团队做系统调整，临时加派人手打包出餐，还能与平台谈判争取配送保底。他们不仅接得住这波流量，打完仗之后还可能获得平台的流量倾斜。可小商户呢？很多人连消息都没接到就被卷进去了。有的直到订单突然暴涨才发现系统根本扛不住，配送费涨了不敢拒绝，抽成也比平时高了不少，但又不得不接。最惨的是，因为履约慢，平台还可能降权，下一轮流量红利就彻底没他们的份了；所以，这场仗表面上是平台在烧钱，实际上压力最大的，是那些没有议价能力的小玩家。当然，也不能忘记消费者。“0元奶茶”让你高频打开App，提升日活；你授权了地理位置权限，平台借此掌握你的消费轨迹；你还慢慢接受了动态定价机制，一杯奶茶涨价几块钱，也开始觉得“好像也没那么离谱”。我自己就有体会：第一天喝肯悦咖啡才4块多，第二天涨到了6块多，到现在几乎恢复原价了。我还特意问了一个不太常点外卖的朋友，他的日常价也才6块多。所以，看似微不足道的变化，在悄悄改写你的消费习惯。而且历史经验告诉我们，低价红利一旦结束，用户流失速度也快得惊人；还记得网约车大战吗？当时订单量暴涨，但补贴一停，用户留存率不到很低。虽然我没有明确数据，说明外卖大战用户留存情况，但一个大家都默认的事实是：平台砸钱换来的增长，往往只是短暂的幻觉。因此，表面上看，这是阿里和美团之间的一场补贴大战；实际上，真正承受代价的，是商家、骑手、消费者，甚至是整个行业的生态平衡。04那么，这场“淮海战役”打到最后，即时零售行业会迎来新大陆吗？短期来看，未来6到12个月是一场拉锯战。阿里的打法很明确，每周末都来一次“7月5日”的翻版，目标是让“超级星期六”变成用户的生活习惯。听起来很美好，但也有风险：用户会不会慢慢疲了？淘宝流量转化率会不会递减？非餐饮品类如生鲜、母婴，履约成本更高，阿里能不能扛得住？美团当然不会坐以待毙。被迫跟进补贴，会不会玩得更精细，比如：在阿里重点城市上线“神枪手”低价专区；用闪电仓密集覆盖高潜力社区，降低最后一公里配送成本？所以，智远认为，双方现在就像两个赌徒，赌谁先停。中期来看，谁先撑不住，谁就出局，到了这个阶段，拼的就是谁能活得更久。这里有三个绕不过去的坎儿：第一个是毛利率陷阱。外卖业务本身毛利还能做到30%左右，但一旦涉及生鲜、冷链这些品类，毛利率直接掉到15%-20%，甚至更低。第二个是运力成本刚性，骑手每单的成本从原来的6-8元涨到了10-12元，而消费者实付却从9-11元降到了0-3元。这不是做生意。第三个是资本耐心见底，美团股价已经比高峰时跌了60%多，市场对亏损的容忍度越来越低；阿里虽然现金流充足，但电商主业也在承压，不可能无限输血。还有一个关键临界点：当单日订单常态化突破1.5亿单时，每增加1000万单，可能就意味着每天多亏2亿元，这已经不是增长，而是出血。那未来的终局是什么样？智远觉得有几个可能性：第一种：垂直分化，美团继续主导餐饮加便利店这类高频需求，阿里掌控生鲜、母婴等高毛利品类；京东聚焦3C数码等高客单价即时配送。第二种：资本合并，美团和阿里成立合资公司，各自划分区域运营；前提是反垄断政策松动，但现在看概率非常低。第三种就是生态重构了，黑天鹅事件，即时零售和社区团购融合，或者无人配送技术突破，直接降低60%的运力成本。所以，即时零售既是绞肉机，也是新大陆，只不过，要先流血，才能看到绿洲。短期内，阿里需要一场“斯大林格勒战役”式的胜利，美团则要避免被拖入消耗战；中期内，谁现金流更稳，谁就能活得更久。目前来看，阿里 账上6137 亿元，美团大概 2000 亿元储备，差距明显；长期来看，30分钟送达将成为像水电煤一样的基础设施，但赢家可能不超过两家。如果拼多多再进来呢？所以，别看现在打得热闹，真正的淘汰赛，才刚刚开始；也许再过一年，当我们站在新起点回看这一切时会发现：如今这场混战，不过是通往未来的第一站。

[00:00] The End of the Core Four [10:25] Marner's legacy and perception in Toronto going forward [26:10] The devastating loss of Pontus Holmberg [34:44] John Tavares signs a team-friendly deal [41:35] Matthew Knies becomes a core player [48:38] Evaluating Steven Lorentz and fourth-line strategy [52:03] The Leafs take a flier on Matias Maccelli [1:03:20] Treliving finds a legit 3C in Nicolas Roy [1:09:27] Some depth contracts + team overview

Dr.Judy Bauer shares the 3C's and how you can apply these attributes to ensure you get the most out of life every day. Visit http://www.epicwin4u.com for links and show notes and join in on the conversation @EpicConqerors on Facebook. If you enjoy our bi-weekly podcasts and videocasts then simply buy us a coffee: https://www.buymeacoffee.com/KingJesus

一项关于携带充电宝登机的新规定让很多旅客猝不及防。中国民航局宣布，禁止旅客携带没有3C标识的充电宝乘坐境内航班，自上周六（6月28日）起生效。什么是3C标识？为何禁止携带没有3C标识的充电宝登机？点击 ▶ 收听完整采访。

最貼近大眾的軍事節目《國防在線急》上線囉

China's aviation regulator has banned uncertified power banks on domestic flights, citing urgent safety concerns over fires and other hazards linked to lithium batteries, State media reported on Wednesday.据官方媒体周三报道，中国航空监管机构以对锂电池相关火灾和其他危险的紧急安全担忧为由，禁止未经认证的充电宝乘坐国内航班。The Civil Aviation Administration of China told People's Daily that quality issues with lithium batteries in power banks have threatened aviation safety, prompting the move. The ban, which took effect on Saturday, applies to power banks without valid China Compulsory Certification — known as 3C — those with unclear 3C labels or those subject to product recalls.中国民用航空局告诉《人民日报》，移动电源锂电池的质量问题已经威胁到航空安全，促使采取了这一行动。该禁令于周六生效，适用于没有有效的中国强制认证（即3C）的电力银行，即3C标签不清楚或产品被召回的电力银行。The 3C certification is a mandatory safety and quality standard for products sold in China. For power banks, it ensures they do not pose risks of fire, electric shock or other hazards. The country began 3C certification for power banks on Aug 1, 2023, and sales of products without the certification have been prohibited since Aug 1 last year.3C认证是在中国销售的产品的强制性安全和质量标准。对于移动电源，它确保它们不会造成火灾、触电或其他危险。该国于2023年8月1日开始对移动电源进行3C认证，自去年8月1日起禁止销售未经认证的产品。The administration said the measure follows a surge in incidents globally involving fires and smoke from lithium batteries on aircraft, including 15 cases in China's aviation sector this year. In one incident on Jan 28, a fire broke out on an Air Busan flight due to a passenger's power bank, damaging the aircraft.美国政府表示，该措施是在全球范围内涉及飞机锂电池火灾和烟雾的事件激增之后采取的，其中包括今年中国航空业的15起案件。在1月28日的一起事件中，釜山航空的一架航班因一名乘客的移动电源发生火灾，导致飞机受损。Lithium batteries are prone to risks under external factors such as high temperatures, pressure and collisions, which can lead to internal short circuits and excessive heat. This can trigger thermal runaway in the battery, resulting in fires or explosions that are difficult to extinguish, the regulator said.美国政府表示，该措施是在全球范围内涉及飞机锂电池火灾和烟雾的事件激增之后采取的，其中包括今年中国航空业的15起案件。在1月28日的一起事件中，釜山航空的一架航班因一名乘客的移动电源发生火灾，导致飞机受损。A recent report from China's market regulation authority found that out of 149 batches of power banks inspected, 65 were substandard, the administration noted.政府指出，中国市场监管机构最近的一份报告发现，在检查的149批电力银行中，有65批不合格。A staff member at Beijing Capital International Airport told China Daily that passengers carrying power banks must now show 3C marks at security checks, and devices under recall will not be allowed through. Power banks under 100 watt-hours can be carried onboard, while those between 100 and 160 watt-hours require airline approval. Devices exceeding 160 watt-hours are prohibited.北京首都国际机场的一名工作人员告诉《中国日报》，携带电动银行的乘客现在必须在安检时出示3C标志，被召回的设备将不允许通过。100瓦时以下的移动电源可以携带登机，而100至160瓦时之间的移动电源需要航空公司的批准。禁止使用超过160瓦时的设备。Noncompliant power banks found during checks will be handled according to passengers' preferences, the administration said. Airports will provide areas for passengers to abandon or temporarily store their devices, along with mailing services for those who wish to send them home.政府表示，在检查过程中发现的不合规移动电源将根据乘客的喜好进行处理。机场将为乘客提供丢弃或临时存放设备的区域，并为希望将设备送回家的乘客提供邮寄服务。Power banks abandoned or left beyond storage deadlines will be destroyed or recycled after consultation with battery recovery companies, the administration said. Records will be maintained throughout storage, transfer and recycling to ensure traceability and prevent unauthorized devices from reentering the market.政府表示，在与电池回收公司协商后，废弃或超过储存期限的移动电源将被销毁或回收。记录将在整个储存、转移和回收过程中得到维护，以确保可追溯性，防止未经授权的设备重新进入市场。lithium batteriesn.锂电池traceabilityn.可追溯性

VOV1 - Sáng 28/6, tại Trụ sở Chính phủ, Thủ tướng Phạm Minh Chính toạ đàm với các doanh nghiệp Vương quốc Anh đang đầu tư tại Việt Nam.- Thủ tướng Phạm Minh Chính chủ trì Tọa đàm với các doanh nghiệp của Vương quốc Anh đang đầu tư tại Việt Nam.- Bí thư Đảng ủy Quốc hội, Chủ tịch Quốc hội Trần Thanh Mẫn dự và chỉ đạo tại Đại hội Đảng bộ Ủy ban Pháp luật và Tư pháp.-Bộ Nội vụ ban hành 'Cẩm nang chính quyền địa phương cấp xã', một tài liệu quan trọng phục vụ công tác đào tạo, bồi dưỡng, hướng dẫn chuyên môn nghiệp vụ cho cán bộ, công chức cấp xã.- Các tỉnh Bắc bộ chủ đọng ứng phó với mưa lớn.- Cả Mỹ và Israel cảnh báo đều có kế hoạch đối phó nhằm vào Iran nếu quốc gia hồi giáo vẫn làm giàu urani đến mức đáng lo ngại.-Trung Quốc cấm mang sạc dự phòng không có nhãn 3C lên máy bay.

VOV1 - Từ hôm nay 28/6, Cục Hàng không Dân dụng Trung Quốc đã chính thức áp dụng quy định mới, cấm hành khách mang theo sạc dự phòng nếu sản phẩm không có nhãn “3C” – một chứng nhận sản phẩm bắt buộc của Trung Quốc - hoặc nhãn mờ, hay thuộc lô đã bị thu hồi, khi làm thủ tục lên máy bay nội địa.

The US president is preparing executive actions to increase energy supply for AI expansion, Threads now offers independent word blocking, and China’s aviation regulator will prohibit passengers from carrying power banks on flights unless they bear the “3C” safety marking. MP3 Please SUBSCRIBE HERE for free or get DTNS Live ad-free. A special thanks toContinue reading "The US President Is Preparing Executive Actions To Increase Energy Supply For AI Expansion – DTH"

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

Welcome to episode 176 of Growers Daily! We cover: garlic curing and storage, the overlooked relationship between manufacturing and farm land, and flower power. But the easy way.  We are a Non-Profit! 

In this episode of The Internal Comms Podcast, host Katie Macaulay sits down with alignment strategist and leadership coach Zora Artis to explore a crucial question: how can internal comms teams unite people around what matters most? It's no easy task, but Zora brings three decades of in-the-trenches experience. As CEO of Artis Advisory, co-founder of the Alignment People and a partner at Mirror Mirror Alignment, her work focuses on getting leaders and teams unstuck and helping organisations untangle competing priorities, find common ground and move forward with confidence. As Zora's research shows, only 13% of organisations achieve real alignment and she explains why diagnosing the real problem matters more than simply turning up the volume on messaging. Misalignment often hides in plain sight, masked by polite nods, surface-level agreement and subtle misunderstandings, she says. Meaningful, facilitated dialogue – not broadcast communication – is often the missing piece. She also introduces her ‘3C+' model and cohesion cycle: practical frameworks to help teams stay agile, find purpose and work as one. Along the way, Zora shares lessons from elite sport, psychology and her own leadership journey, where curiosity, courage and a little discomfort all play a role. As always, we'd love to hear your thoughts. Use the hashtag #TheICPodcast to join the conversation, and thank you for listening.

－挺你所想！與你一起生活的銀行－ 中國信託銀行APP超越大升級， 眾多好用功能，力挺你的金融需求！ 趕緊註冊行動銀行，就送OPENPOINT100點。 立即點擊連結看活動詳情～ https://sofm.pse.is/7nyp36 -- 住近美術館，把握最後機會 《惟美術》3房熱銷倒數 輕奢品味，全新完工，即刻入住 近鄰輕軌C22站，設籍明星學區 預約來電 07-553-3838 https://sofm.pse.is/7nyp2z －－－－以上訊息由 SoundOn 動態廣告贊助商提供－－－－ 飛碟聯播網《飛碟早餐 唐湘龍時間》2025.06.03 週二醫療保健單元 專訪：台大醫院眼科部主治醫師｜楊中美 主題：《好眼力：台大眼科名醫楊中美教你正確認識及防護眼睛疾病》天下文化 好書收藏 https://reurl.cc/pajqr4 對抗3C時代惡視力！你一定要知道的眼疾與保健觀念 擁有正確的護眼知識，能有效從源頭杜絕眼睛疾病的發生 台大眼科楊中美醫師行醫與教學40餘年，看診名額一位難求，寶貴知識經驗首度出版成冊。本書涵蓋多領域眼科知識，幫助大眾破解常見護眼保健迷思，有效從源頭杜絕眼睛疾病的發生。 作者簡介 楊中美 台大醫學系畢業，台大醫學院名譽教授、中華民國視網膜醫學會共同創始人。現為台大醫院眼科部主治醫師，曾任台大醫院眼科部主任、中華民國視網膜醫學會理事長。專長於視網膜及玻璃體疾患之診治。 身為國際視網膜領域著名學者，多次受邀於亞太眼科醫學會、亞太玻璃體視網膜學會、各國眼科醫學會、兩岸眼科醫學會等學會演講。2016年當選亞太眼科教授學院院士，並獲頒亞太眼科醫學會成就獎。 常以「術精德厚」自勉，持續專注於糖尿病視網膜病變與黃斑部疾患的診治、教學及前沿研究，推廣大眾的眼部保健。 #眼睛 #眼科#視網膜#台大醫院#楊中美#黃斑部#白內障#飛蚊症#醫療#保健#視力#老花眼 ▶ 《飛碟早餐》FB粉絲團  / ufobreakfast  ▶ 飛碟聯播網FB粉絲團  / ufonetwork921  ▶ 網路線上收聽 http://www.uforadio.com.tw ▶ 飛碟APP，讓你收聽零距離 IOS：https://reurl.cc/3jYQMV Android：https://reurl.cc/5GpNbR ▶ 飛碟Podcast Apple Podcasts : https://apple.co/3jFpP6x Spotify : https://spoti.fi/2CPzneD KKBOX：https://reurl.cc/MZR0K4 -- Hosting provided by SoundOn

高雄美術特區3-4房全新落成，《惟美術》輕軌C22站散步即到家，近鄰青海商圈，卡位明星學區，徜徉萬坪綠海。 住近美術館，擁抱優雅日常，盡現驕傲風範！美術東四路29號 07-553-3838 https://sofm.pse.is/7melqb --

In this episode Zackavelli talks about the 3C's Game Design Framework Skip to Body of Episode: 6:15 Become a Patron: www.patreon.com/GDFG Join the discord and talk with the community about making video games! Link: discord.gg/2C8eTsU Follow Zackavelli on Twitter @_Zackavelli_ Twitch: www.twitch.tv/zackavelli_ Intro music by: Avaren Outro remix by: Mugamoomoo

Phoebe and Randy's meet‑cute at the gas station morphed into a mid‑40s tag‑team battle with blood sugars: hers since age 12, his brand‑new after pancreatic cancer left him with type 3C diabetes. Tandem Mobi ** twiist AID System Free Juicebox Community (non Facebook) JUICE CRUISE 2025 Blue Circle Health Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!